



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

27 April 2017
EMA/270583/2017
Inspections Human Medicines Pharmacovigilance Division
Committees and Inspections Department

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Non-replicating recombinant Adeno associated virus (rAAV8), expressing the human UGT1A1 gene.

Brief description of the finished product

Suspension of product vector particles for i.v. injection.

Proposed indication

Treatment of Crigler-Najjar syndrome.

EMA/CAT conclusion

The procedure was finalised on 29 March 2017 for the following recommendation.

On the basis that:

- the product contains a biological medicinal product as the active substance;



- the active substance is a recombinant nucleic acid administered to human beings with a view to adding a genetic sequence;
- its therapeutic effect relates directly to the product of the genetic expression of this sequence,

the EMA/CAT considers that the Product falls within the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.